Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

May 12, 2017: By Jon Swedien

Hoya logoHoya’s intraocular lens (IOL) sales were strong during its fiscal 2017 fourth quarter—Jan. 1 to March 31, 2017, according to the Japanese company.

The firm announced May 11 that its IOL sales for cataracts continued to perform well in Japan, after being introduced in the previous fiscal year. Outside of Japan, IOL sales grew, outpacing performance for the same period in the prior fiscal year “by a significant margin,” Hoya said.

Hoya’s Life Care business segment, which includes eyeglass lenses, contact lenses, and intraocular lenses (IOLs), plus other products, saw an increase in revenues of 3.5 percent, with sales totaling 83,752 million yen (US $739 million, as of May 12, 2017) in the quarter.

Hoya reported that its overall revenues increased 3.8 percent to 126,304 million yen (US $1.12 billion) in the company’s 2017 fiscal fourth quarter.

Revenues for the fiscal year ended March 31, 2017, totaled 478,927 million yen (US $4.23 billion), down 5.3 percent year over year.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022